Skip to main content
TipRanks
Go Ultimate75% OFF

Atrium Therapeutics, Inc. (RNA) Stock Forecast & Price Target

25 Followers
See the Price Targets and Ratings of:

RNA Analyst Ratings

Strong Buy
4Ratings
4Buy0Hold0Sell
Based on 4 analysts giving stock ratings to Atrium Therapeutics, Inc. in the past 3 months

RNA Stock 12 Month Forecast

$21.25▲(182.96% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Atrium Therapeutics, Inc. in the last 3 months. The average price target is $21.25 with a high forecast of $25.00 and a low forecast of $15.00. The average price target represents a 182.96% change from the last price of $7.51.
Highest Price Target$25.00Average Price Target$21.25Lowest Price Target$15.00

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for RNA
Price TargetArticle
Wells Fargo$25buy232.89%UpsideAssigned11/16/26
Roth MKM$15buy99.73%UpsideReiterated11/13/26
H.C. Wainwright$20buy166.31%UpsideReiterated11/13/26
Cantor Fitzgerald$25buy232.89%UpsideReiterated10/14/26
Leerink Partners$25buy232.89%UpsideInitiated05/15/26
Stocks with the Highest Top Analyst Consensus in the General Sector
STDNStandard Nuclear
SKHYSK Hynix
ITGITG Inc. Class A
LIMENeutron Holdings, Inc.
EROCERock

Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Atrium Therapeutics, Inc.

3 Months
Mitchell Kapoor
Mitchell KapoorH.C. Wainwright
Success Rate0/3 ratings generated profit
0%
Average Return
-13.87%

Copying Mitchell Kapoor's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -13.87% per trade.

1 Year
Mitchell Kapoor
Mitchell KapoorH.C. Wainwright
Success Rate0/3 ratings generated profit
0%
Average Return
-16.13%

Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -16.13% per trade.

2 Years
Mitchell Kapoor
Mitchell KapoorH.C. Wainwright
Success Rate0/3 ratings generated profit
0%
Average Return
-16.13%

Copying Mitchell Kapoor's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -16.13% per trade.

RNA Analyst Recommendation Trends

02468Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for RNA
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy36587
Buy00000
Hold00000
Sell00000
Strong Sell00000
total36587

In the current month, RNA has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RNA average Analyst price target in the past 3 months is 21.25.

RNA Financial Forecast

RNA Stock Forecast FAQ

What is RNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Atrium Therapeutics, Inc.’s 12-month average price target is $21.25.
What is RNA’s upside potential, based on the analysts’ average price target?
Atrium Therapeutics, Inc. has 182.96% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RNA a Buy, Sell or Hold?
Atrium Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Atrium Therapeutics, Inc.’s price target?
The average price target for Atrium Therapeutics, Inc. is $21.25. This is based on 4 12-month price targets, issued in the past 3 months. The highest analyst price target is $25.00, the lowest forecast is $15.00. The average price target represents a 182.96% increase from the current price of $7.51.
What do analysts say about Atrium Therapeutics, Inc.?
Atrium Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Street analysts.
How can I buy shares of RNA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.